Key Takeaway: Molecular Partners has provided an update on its Phase 1/2a trial of MP0712, a DLL3-targeted Radio-DARPin co-developed with Orano Med. Dosing is currently ongoing in the first patients, with initial data expected in the coming months. Comprehensive efficacy data is projected to be available by 2027, indicating significant future insights into the treatment's effectiveness.
Price reaction · baseline $3.98 (2026-07-02 close) · hit pre-market · clean, no other MOLN news in the window
day 0 close · peak
+0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Ongoing dosing in first patients shows progress.
Initial data expected soon indicates timely development.
Comprehensive efficacy data anticipated by 2027.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.3%
average across 2 past catalysts
Lead asset
ensovibep
Phase 2 · Covid19
Full Press Release Details
Phase 1/2a trial of MP0712, 212 Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 Additional compassionate care work now initiated by the Nuclear
Frequently Asked Questions
What is the focus of the MP0712 trial?
The MP0712 trial focuses on a DLL3-targeted Radio-DARPin for treating cancer.
When is initial data from the trial expected?
Initial data from the MP0712 trial is anticipated within the coming months.
Who is co-developing MP0712?
MP0712 is co-developed by Molecular Partners and Orano Med.
What is the timeline for comprehensive efficacy data?
Comprehensive efficacy data for MP0712 is expected to be available in 2027.